Global Anti-Rheumatics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Disease Modifying Anti-Rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others.

By Type;

Prescription-Based Drugs and Over-the-Counter Drugs.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn543744279 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Anti-Rheumatics Market (USD Million), 2021 - 2031

In the year 2024, the Global Anti-Rheumatics Market was valued at USD 68,014.68 million. The size of this market is expected to increase to USD 83,195.75 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 2.9%.

The Global Anti-Rheumatics Market encompasses a wide array of pharmaceutical interventions aimed at alleviating symptoms and managing the progression of rheumatic diseases. These conditions, characterized by inflammation and pain in the joints, muscles, and connective tissues, pose significant challenges to patients and healthcare providers worldwide. The market's growth is driven by various factors, including advancements in treatment modalities, increasing prevalence of rheumatic disorders, and growing awareness about the importance of early diagnosis and intervention.

Anti-rheumatic medications play a pivotal role in the management of rheumatic diseases, offering relief from pain and inflammation while also addressing underlying disease mechanisms. This market is characterized by a diverse range of drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biologic agents, and corticosteroids, each tailored to target specific aspects of the disease process.

The global anti-rheumatics market is poised for significant growth, driven by the increasing burden of rheumatic diseases and the growing demand for effective treatment options. Stakeholders must navigate various challenges while capitalizing on emerging opportunities to ensure the delivery of safe, accessible, and innovative therapies to patients worldwide.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Type
    3. Market Snapshot, By Region
  4. Global Anti-Rheumatics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing prevalence of rheumatic diseases
        2. Aging population
        3. Rising awareness and early diagnosis
        4. Growing healthcare expenditure
        5. Adoption of combination therapies
      2. Restraints
        1. Adverse medication side effects
        2. Stringent regulations
        3. Patent expirations
        4. Slow drug approvals
        5. Patient adherence issues
      3. Opportunities
        1. Development of biosimilars
        2. Innovative drug delivery systems
        3. Telemedicine growth
        4. Personalized medicine
        5. Preventive care focus
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Anti-Rheumatics Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Disease Modifying Anti-Rheumatic Drugs
      2. Nonsteroidal Anti-inflammatory Drugs
      3. Corticosteroids
      4. Uric Acid Drugs
      5. Others
    2. Global Anti-Rheumatics Market, By Type, 2021 - 2031 (USD Million)
      1. Prescription-Based Drugs
      2. Over-the-Counter Drugs
    3. Global Anti-Rheumatics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. AbbVie Inc.
      2. Pfizer Inc.
      3. Novartis AG
      4. Amgen Inc.
      5. Johnson & Johnson
      6. Merck & Co., Inc.
      7. Roche Holding AG
      8. Bristol Myers Squibb Company
      9. Eli Lilly and Company
      10. GlaxoSmithKline plc
      11. AstraZeneca PLC
      12. Takeda Pharmaceutical Company Limited
      13. Biogen Inc.
      14. Sanofi S.A.
      15. Boehringer Ingelheim International GmbH
  7. Analyst Views
  8. Future Outlook of the Market